We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Inhalon Biopharma today announced that it has been awarded a $7 million contract by the U.S. Army Medical Research & Development Command to conduct a placebo-controlled Phase 1/2a study of IN-006 in COVID-19 outpatients.